In fiscal year 2025, Chong Kun Dang Pharmaceutical (185750) reported revenue of 1.69 trillion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 1.69 trillion KRW | 80.6 billion KRW | 77.8 billion KRW | [source] |
| 2024 | 1.59 trillion KRW | 99.5 billion KRW | 111.4 billion KRW | [source] |
| 2023 | 1.67 trillion KRW | 246.6 billion KRW | 213.6 billion KRW | [source] |
| 2022 | 1.49 trillion KRW | 109.9 billion KRW | 80.0 billion KRW | [source] |
| 2021 | 1.34 trillion KRW | 94.8 billion KRW | 42.4 billion KRW | [source] |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 1.79 trillion KRW | 783.2 billion KRW | 1.00 trillion KRW | [source] |
| 2024 | 1.43 trillion KRW | 545.7 billion KRW | 884.7 billion KRW | [source] |
| 2023 | 1.38 trillion KRW | 569.1 billion KRW | 807.7 billion KRW | [source] |
| 2022 | 1.10 trillion KRW | 479.0 billion KRW | 618.0 billion KRW | [source] |
| 2021 | 1.02 trillion KRW | 457.4 billion KRW | 559.8 billion KRW | [source] |